Retatrutide vs Sermorelin: price per mg, identity and regulatory status (2026)
Retatrutide and Sermorelin are different research compounds, not substitutes for each other: Retatrutide is a single compound (C221H342N46O68); Sermorelin is a 29-amino-acid peptide (C149H246N44O42S). Lowest current in-stock prices: Retatrutide 30mg from $199.99 ($6.67/mg) at Amino Club; Sermorelin 5mg from $49.99 ($10.00/mg) at Nova Peptide Supply. Retatrutide has no Drugs@FDA application; Sermorelin was FDA-approved but every application is discontinued.
Research use only. These are research-use-only listings sold for laboratory research, not prescription medicines and not for human use. PeptideTech does not compare effects or provide dosing information.
Retatrutide vs Sermorelin: current prices and packages
| Compared property | Retatrutide | Sermorelin |
|---|---|---|
| Category | GLP-1 | Growth hormone |
| Compared package | 30mg · Vial | 5mg · Vial |
| Lowest current price | $199.99 at Amino Club, checked Oct 14, 2026 | $49.99 at Nova Peptide Supply, checked Oct 16, 2026 |
| Price per labelled mg | $6.67/mg | $10.00/mg |
| Package sizes | 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 48mg, 50mg, 60mg | 2mg, 5mg, 10mg, 15mg |
| Vendors with current prices | 2 (3 tracked) | 3 |
| Form at this package | Vial | Vial |
| Stock | In stock | In stock |
Prices exclude shipping. The price per labelled mg is always given per mg, so different package sizes compare directly; it is shown only for single-compound vials and powders with a labelled mass. Blends, capsules, liquids and IU-labelled packages are compared by package total.
Identity, regulatory status and registered research
| Compared property | Retatrutide | Sermorelin |
|---|---|---|
| Molecular formula | C221H342N46O68 | C149H246N44O42S |
| Molecular weight | 4731 g/mol | 3357.9 g/mol |
| Sequence | — | H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 (29 residues) |
| CAS Registry Number | — | 86168-78-7 |
| Registered clinical trials | 34 (11 active) · Phase 3: 14, Phase 2: 4, Phase 1: 15 | None recorded |
| Human intervention studies | 7 | 2 |
| US regulatory status | No Drugs@FDA application (checked October 7, 2026) · Drugs@FDA search | FDA-approved as Geref, all applications discontinued (NDA 019863 and NDA 020443; checked October 7, 2026)DiscontinuedGEREF · NDA 019863 · 1990GEREF · NDA 020443 · 1997Research listings are not these medicines. |
Identity data: PubChem, FDA GSRS and EPA records; registry counts: ClinicalTrials.gov; status: Drugs@FDA. A matching name does not verify the contents of a supplier's lot.
Key human studies
Retatrutide
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet (London, England), 2026
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The lancet. Diabetes & endocrinology, 2025
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine, 2024
Sermorelin
- Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. The Journal of clinical endocrinology and metabolism, 1996
- A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency. Acta paediatrica (Oslo, Norway : 1992). Supplement, 1993
Studies are listed as records, newest first; they are not evidence that a research product is safe or effective.
Research-use listings for each compound
Research-use-only listings sold for laboratory research, not prescription medicines and not for human use.
Retatrutide
Retatrutide, also identified as LY3437943, is an investigational agonist at GIP, GLP-1 and glucagon receptors. A peer-reviewed phase 2 trial and a later sponsor-described phase 3 program are different levels of source evidence.
$199.99 · 30mg · $6.67/mg · Amino Club
View at Amino Club, Retatrutide 30mg, opens in a new tabPeptideTech does not sell or fulfill products. Some outgoing links can earn a commission, which does not determine price order. How we rankRetatrutide prices →Price history →Sermorelin
Sermorelin is a catalogue entry whose compound-specific reference review has not yet been completed.
$49.99 · 5mg · $10.00/mg · Nova Peptide Supply
View at Nova Peptide Supply, Sermorelin 5mg, opens in a new tabPeptideTech does not sell or fulfill products. Some outgoing links can earn a commission, which does not determine price order. How we rankSermorelin prices →Price history →Related comparisons
Questions
Automated price sources are scheduled daily; other sources are checked manually. Check the offer's last successful source timestamp. A code is shown when it is attached to an offer or affiliate link. The displayed price includes a discount only when that code is cart-verified and the discounted price is explicitly recorded; otherwise it is the vendor's listed price. Prices exclude shipping. Stock status is captured at the same time. Rankings are by displayed price only. PeptideTech earns a commission when you buy through a link; it never changes the order.
Full method →